-+ 0.00%
-+ 0.00%
-+ 0.00%

Baird Initiates Coverage On Caris Life Sciences with Outperform Rating, Announces Price Target of $26

Benzinga·02/17/2026 10:20:20
Listen to the news
Baird analyst Catherine Schulte initiates coverage on Caris Life Sciences (NASDAQ:CAI) with a Outperform rating and announces Price Target of $26.